Biocompatibility in cardiopulmonary bypass

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 3, 1997, Pages 376-382

  Hsu, Li Chien ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

biocompatibility; blood material interactions; cardiopulmonary bypass; control of blood activation; heparin coating

Indexed keywords

BIOCOMPATIBILITY; BLEEDING TENDENCY; BLOOD CLOTTING; BLOOD FLOW VELOCITY; CARDIOPULMONARY BYPASS; CARDIOPULMONARY HEMODYNAMICS; CELL INTERACTION; COMPLEMENT ACTIVATION; EXTRACORPOREAL CIRCULATION; HUMAN; OXYGENATOR; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE;

EID: 0030912108     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(97)90108-7     Document Type: Review

References (79)

1. Scott WJ, Rode R, Castelmain B, et al: Efficacy, complication and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg 103:1001-1007, 1992
2. Tabuchi N, de Haan J, Boonstra PW, et al: Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 106:828-833, 1993
3. Schonberger JPAM, Everts PAM, Hoffmann JJ: Systemic blood activation with open and closed venous reservoir. Ann Thorac Surg 59:1549-1555, 1995
4. Valeri CR, Khabbaz K, Khuri SF, et al: Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg 104:108-116, 1992
5. Varrier E: The microvascular cell and ischemia-reperfusion injury. J Cardiovasc Pharmacol 27:526-530, 1996 (suppl 1)
6. MacFarlane RG: An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 202:498, 1964
7. 1+2. Thromb Haemost 70:253-258, 1993
8. Gu YJ, van Oeveren W, van der Kamp KWHJ, et al: Heparin coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 6:221-225, 1991
9. Spanier T, Oz M, Levin H, et al: Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 112:1090-1097, 1996
10. Despotis GJ, Levine V, Alsoufiev A, et al: Recurrent thrombosis of biventricular-support devices associated with accelerated intravascular coagulation and increased heparin requirements. J Thorac Cardiovasc Surg 112:538-540, 1996
11. Cavarocchi NC, Schaff HV, Orszulak TA, et al: Evidence for complement activation by heparin-protamine interaction after cardiopulmonary bypass. Surgery 98:525-531, 1985
12. Rinder C, Fitch J: Amplification of the inflammatory response: Adhesion molecules associated with platelet/white cell responses. J Cardiovasc Pharmacol 27:S6-S12, 1996 (suppl 1)
13. Hardy J, Desroches J: Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth 39:353-365, 1992
14. Khuri SF, Michelson AD, Valeri CR: Effects of cardiopulmonary bypass on hemostasis, in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Cambridge, UK, Blackwell, 1993, pp 1051-1073
15. Kevy SV, Glickman RM, Bernhard WF, et al: The pathogenesis and control of the hemorrhagic defect in open heart surgery. Surg Gynecol Obstet 123:313-318, 1996
16. Hsu LC: Biocompatibility in heparin-coated extracorporeal circuits. Perfusion 11:256-263, 1996
17. Malinauskas RA, Sade RM, Dearing JP, et al: Blood damage in cardiotomy suction return. J Extracorpor Technol 20:40-45, 1988
18. Kirklin JK: The Postperfusion Syndrome: Inflammation and the Damaging Effects of Cardiopulmonary Bypass: Current Concepts and Controversies, Philadelphia, PA, Saunders, 1989, p 131
19. Kongsgaard UE, Smith-Erichsen N, Geiran O, et al: Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery. Acta Anaesthesiol Scand 33:343-347, 1989
20. Edmunds LH Jr: Breaking the blood-biomaterial barrier. ASAIO J 41:824-830, 1995
21. Westaby S, Fleming JS, Royston D: Acute lung injury during cardiopulmonary bypass: The role of neutrophil sequestration and lipid peroxidation. ASAIO J 31:604, 1985
22. Pober JS, Contran RS: Cytokines and endothelial cell biology. Physiol Rev 70:427-451, 1990
23. Hennein HA, Ebba H, Rodriguez JL, et al: Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 108:626-635, 1994
24. Verrier ED, Boyle EM: Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg 62:915-922, 1996
25. te Velthuis H, Jansen PGM, Oudemans-van Straaten HM, et al: Circulating endothelin in cardiac operations: Influence of blood pressure and endotoxin. Ann Thorac Surg 61:904-908, 1996
26. Johnson MJ, Pohlman TH, Verrier ED: Neutrophil antiadhesion therapy for myocardial ischemia: Clinical potential. Clin Immunother 3:8-14, 1995
27. van Oeveren W, Jansen NJG, Bidstrup BP, et al: Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44:640-645, 1987
28. Seghaye M-C, Duchateau J, Grabitz RG, et al: Influence of low-dose aprotinin on inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg 61:1205-1211, 1996
29. Speekenbrink RGH, Wildevuur CRH, Sturk A, et al: Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg 112:523-530, 1996
30. Usui A, Hiroura M, Kawamura M, et al: Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials. Ann Thorac Surg 62:1404-1411, 1996
31. Sawa Y, Shimazaki Y, Kadoba K, et al: Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg 111:29-35, 1996
32. Bidstrup BP, Royston D, Sapsford RN, et al: Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin. J Thorac Cardiovasc Surg 97:364-372, 1989
33. Vander Salm T, Kaur S, Lancey RA, et al: Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 112:1098-1117, 1996
34. Rousou JA, Engelman RM, Flack JE, et al: Tranexamic acid significantly reduces blood loss associated with coronary revascularization. Ann Thorac Surg 59:671-675, 1995
35. Katsaros D, Petricevic M, Snow NJ, et al: Tranexamic acid reduces postbypass blood use: A double-blinded, prospective, randomized study of 210 patients. Ann Thorac Surg 61:1131-1135, 1996
36. Fullerton DA, McIntyre RC: Inhaled nitric oxide: Therapeutic applications in cardiothoracic surgery. Ann Thorac Surg 61:1856-1864, 1996
37. Vertrees RA, Conti VR, Lick SD, et al: Adverse effects of postoperative infusion of shed mediastinal blood. Ann Thorac Surg 62:717-723, 1996
38. Bando K, Pillai R, Cameron DE, et al: Leukocyte depletion ameliorates free-radical mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:873-897, 1990
39. Mihaljevic T, Tonz M, von Segesser LK, et al: The influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function. J Thorac Cardiovasc Surg 109:1138-1145, 1995
40. Al-Ebrahim, Shafei H: Pall leukocyte depleting filter during cardiopulmonary bypass [letter]. Ann Thorac Surg 58:1560-1561, 1994
41. Gu YJ, de Vries AJ, Boonstra PW, et al: Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac Surg 112:494-500, 1996
42. Bellomo R: Continuous hemofiltration as blood purification in sepsis. New Horizons 3:732-737, 1995
43. Coraim F, Wolner E: Continuous hemofiltration for the failing heart. New Horizons 3:725-731, 1995
44. Blauth C, Smith PL, Arnold JV, et al: Influence of oxygenator type on the incidence and extent of microembolic retinal ischemia during cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:61-69, 1990
45. Pfaender LM: Hemodynamics in extracorporeal aortic cannula: Review of factors affecting the choice of appropriate size. J Extracorporeal Tech 13:224-232, 1981
46. Borowiec JW, Bylock A, van der Linden J, et al: Heparin coating reduces blood cell adhesion to arterial filter during coronary bypass: A clinical study. Ann Thorac Surg 55:1540-1545, 1993
47. Hsu LC: Heparin-coating of bypass circuits: Principles of heparin-coating techniques. Perfusion 6:209-219, 1991
48. Hsu LC: Duraflo II heparin immobilized cardiopulmonary bypass circuits, in Ott RA et al (eds): Cardiac Surgery: State of the Art Reviews. Philadelphia, PA, Hanely & Belfus, 1993, pp 265-276
49. Hsu LC: Issue of biocompatibility, in Stammers AH (ed): International Anesthesiology Clinics. Cardiopulmonary Bypass: Emerging Trends and Continued Practices. Boston, MA, Little Brown. 1996, pp 109-122
50. Gravlee GP: Heparin-coated cardiopulmonary bypass circuits. J Cardiothorac Vasc Anesthesia 8:213-222, 1994
51. Korn RL, Fisher CA, Livingston ER, et al: The effects of Carmeda bioactive surface on human blood components during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 111:1073-1084, 1996
52. Pradhan MJ, Fleming JS, Nkere UU, et al: Clinical experience with heparin-coated cardiopulmonary bypass circuits. Perfusion 6:235-242, 1991
53. Muehrcke DD, McCarthy PM, Kottke-Marchant K, et al: Biocompatibility of heparin-coated extracorporeal circuits: A randomized, masked clinical trial. J Thorac Cardiovasc Surg 112:472-483, 1996
54. Gorman RC, Ziats NP, Rao AK, et al: Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 111:1-12, 1996
55. Boisclair M, Lane DA, Philippou H, et al: Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82:3350-3357, 1993
56. Ovrum E, Holen EA, Tangen G, et al: Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects. Ann Thorac Surg 60:365-371, 1995
57. Ovrum E, Brosstad F, Holen EA, et al: Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 92:2597-2584, 1995
58. Gu YJ, van Oeveren W, Akkerman C, et al: Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55:917-922, 1993
59. Jansen PGM, te Velthuis H, Huybregts RAJM, et al: Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 110:829-834, 1995
60. te Velthuis H, Jansen PGM, Hack CE, et al: Specific complement inhibition with heparin-coated extracorporeal circuits. Ann Thorac Surg 61:1153-1157, 1996
61. Weerwind PW, Maessen JG, van Tits LJH, et al: Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 110:1633-1641, 1995
62. Yamada H, Kudoh I, Hirose Y, et al: Heparin-coated circuits reduce the formation of TNFa during cardiopulmonary bypass. Acta Anaesthesiol Scand 40:311-317, 1996
63. Moen O, Hogasen K, Anderson C, et al: Changed expression of adhesion molecules on granulocytes, monocytes and thrombocytes in heparin-coated cardiopulmonary bypass. Abstract in Pathophysiology and Techniques of Cardiopulmonary Bypass. San Diego, CA, Cardiothoracic Research and Education Foundation, 1995, p 203
64. Ranucci M, Cirri S, Conti D, et al: Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction. Ann Thorac Surg 61:76-81, 1996
65. Jansen PGM, Baufreton C, LeBesnerais P, et al: Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann Thorac Surg 61:1363-1366, 1996
66. Penka M, Hagman L, Halden E, et al: Complement activation during cardiopulmonary bypass: Effects of immobilized heparin. Ann Thorac Surg 58:421-424, 1994
67. Fosses E, Moen O, Johnson E, et al: Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 58:472-477, 1994
68. Ovrum E: Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass. Ann Thorac Surg 61:1038-1039, 1996
69. Ovrum E, Mollnes TE, Fosse E, et al: High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Ann Thorac Surg 60:1755-1761, 1995
70. von Segesser LK, Weiss BK, Pasic M, et al: Risks and benefits of low systemic heparinization during open heart operations. Ann Thorac Surg 58:391-398, 1994
71. Aldea GS, Shapira OM, Treanor PR, et al: Effective use of heparin-bonded circuits and lower anticoagulation for coronary artery bypass grafting in Jehovah's witnesses. J Card Surg 11:12-17, 1996
72. Aldea GS, Doursounian M, O'Gara P, et al: Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective, randomized study. Ann Thorac Surg 62:410-418, 1996
73. Merrill E, Salzman EW: Polyethylene oxide as a biomaterial. ASAIO J 6:60-64, 1983
74. Kottke-Marchant K, Anderson JM, Umemura Y, et al: Effect of albumin coating on the in vitro blood compatibility of Dacron arterial prostheses. Biomaterials 10:147-155, 1989
75. Bonser RS, Dave JR, Davies ET, et al: Reduction of complement activation during bypass by prime manipulation. Ann Thorac Surg 49:279-283, 1990
76. Marelli D, Paul A, Samson R, et al: Does the addition of albumin to the prime solution in cardiopulmonary bypass affect clinical outcome? A prospective randomized study. J Thorac Cardiovasc Surg 98:751-756, 1989
77. Ishihara K, Takayama R, Nakabayashi N, et al: Improvement of blood compatibility on cellulose dialysis membrane. Biomaterials 13:235-239, 1992
78. Herring MB, Baughman S, Glover J, et al: Endothelial seeding of Dacron and polytetrafluoroethylene grafts: The cellular events of healing. Surgery 96:745-754, 1984
79. Slater JP, Rose E, Levin HR, et al: Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg 62:1321-1328, 1996